The upcoming data from the twin trials, named TOPAZ-1 and TOPAZ-2, marks the company's first major lupus trial readout since it reported positive Phase 3 results for another drug, dapirolizumab, more than two years ago. Biogen is preparing to announce the results from both Phase 3 studies evaluating litifilimab in the first half of December. These findings will serve as an important benchmark for the growth strategy introduced by Chris Viehbacher. A positive outcome would help solidify the executive team's revised vision for the company's experimental portfolio.
Key points
The upcoming readout serves as a critical test for Biogen's research and development over…: The upcoming readout serves as a critical test for Biogen's research and development overhaul.
litifilimab results will act as an important measure of CEO Chris Viehbacher's strategic…: litifilimab results will act as an important measure of CEO Chris Viehbacher's strategic leadership.
The twin Phase 3 studies represent a significant yet risky development milestone for the…: The twin Phase 3 studies represent a significant yet risky development milestone for the company.
Sources checked by our analysis pipeline: 1
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.
More than two years have passed since Biogen announced results from a Phase 3 study in lupus. The drug was dapirolizumab and the outcome was positive, in case you were wondering. In the first half of December, Biogen will hope for a repeat, and once again, it’s another lupus drug, litifilimab, that is being evaluated in twin Phase 3 studies.
The looming readout from the TOPAZ-1 and TOPAZ-2 studies is an important test of the R&D revamp and growth strategy that Biogen CEO Chris Viehbacher implemented when he joined the company in 2022. It’s also risky.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
The HollyRod Foundation presented Samuel L. Jackson and LaTanya Richardson Jackson with the Clarence and Jacqueline Avant HollyRod Humanitarian Award during the 27th annual DesignCare Gala in Los Angeles. This recognition highlights the couple's extensive community advocacy alongside an organization supporting individuals affected by autism and Parkinson’s disease. During the event, Jackson reflected on his long-standing friendship with the award's late namesakes.
A massive search involving over 100 first responders led authorities to the wooded area near Batesburg-Leesville after an infant disappeared from family care. Investigators noted recent domestic friction between the child's parents, though an official motive remains unconfirmed. The suspect faces multiple serious charges and has a prior criminal record from earlier this year involving assault and domestic violence.
Food and Drug Administration has shelved its commissioner's voucher program aimed at providing speedy drug reviews, according to sources. Further details regarding the reasons for the decision or the future of the initiative were not disclosed.